Roquefort Therapeutics plc
- Jurisdiction
United Kingdom - LEI
254900P4SISIWOR9RH34 - ISIN
GB00BMDQ2T15 (ROQ.L )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
Roquefort Therapeutics plc operates as a biotechnology research company. Read full profile
Stock price
Fundamentals
- Net revenue
€233.23K - Gross margin
87.5% - EBIT
-€1.99M - EBIT margin
-853.1% - Net income
-€3.66M - Net margin
-1,567.4%
Statement period: - (published )
Dividends
No dividend payouts